In this Keynote Webinar, sponsored by Illumina, two leading researchers will show how genomic technologies are tackling the COVID-19 pandemic—Alex Greninger, MD, PhD, (University of Washington School of Medicine) and Darrell Dinwiddie PhD, (University of New Mexico Health Sciences Center).
Download this eBook to learn how MolecularMD helped usher in a new era of CML treatment now prescribed by progressive clinicians.
Codevelopment is an intermittent and uncertain process. Adopting an agnostic approach to the challenges associated with platform and method selection provide added degrees of freedom for strategic development and selection of the most appropriate clinical trial assay.
Oxford Nanopore’s DNA/RNA sequencing technology delivers ultra-long reads (up to 2 Mb), enabling rapid and comprehensive analysis of variants. With devices scalable from portable to benchtop, nanopore sequencing offers a cost-effective solution to the challenges faced by traditional sequencing platforms.
This webinar focuses on scientific, clinical, and patient-oriented strategies to help WGS's high clinical expectations.
Target Enrichment Technology Optimized for Analysis of SNPs, Mutations, and Copy Number Changes in...
During this webinar we will describe and present data for an NGS target enrichment workflow, based on the novel SPET.
2015 was a phenomenal year full of new developments for the structures and mechanisms of CRISPR systems.
Digital Insights to Tumor Biology is a complimentary, half-day virtual event dedicated to embracing not just the power of digital pathology but the value of partnerships and end-to-end workflows to better serve the scientific community. This complimentary digital event will address critical issues around biomarker development.
Takeda has taken great strides in incorporating a patient-centric approach to drug development through the use of minimally invasive and less frequent testing procedures while maintaining the power and rigor of the clinical trial.
Join us for this live Clinical OMICs webinar, sponsored by Natera, for a dynamic discussion with our esteemed guests Dr. Gregory Botta from UC San Diego and Dr. Angel Rodriguez from Natera, who will review the value of a tumor informed approach to optimize patient management in the adjuvant treatment setting.